Stocklytics Platform
Asset logo for symbol ATXS
Astria Therapeutics
ATXS54
$9.37arrow_drop_down7.03%-$0.70
Asset logo for symbol ATXS
ATXS54

$9.37

arrow_drop_down7.03%

Performance History

Chart placeholder
Key Stats
Open$10.17
Prev. Close$10.09
EPS-2.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range9.10
10.99
52 Week Range4.26
16.90
Ratios
Revenue-
EBITDA Margin %-
EPS-2.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Astria Therapeutics (ATXS)

Astria Therapeutics, Inc. (ATXS) is a biopharmaceutical company focused on the development of innovative therapies for various diseases. The company's stock price history has been relatively stable, with gradual growth over the years. Investors have shown a positive sentiment towards Astria Therapeutics, resulting in a steady increase in its stock price.
Astria Therapeutics is known for its dedication to research and development, constantly working on groundbreaking treatments that can potentially improve patients' lives. The company has a strong pipeline of drugs, with several candidates in various stages of clinical trials. This indicates that Astria Therapeutics is committed to bringing novel therapies to market.
Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Jill C. Milne Ph.D.
Headquarters
Boston
Employees
45
Exchange
NASDAQ
add Astria Therapeutics to watchlist

Keep an eye on Astria Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Astria Therapeutics's (ATXS) price per share?

The current price per share for Astria Therapeutics (ATXS) is $9.37. The stock has seen a price change of -$0.71 recently, indicating a -7.04% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Astria Therapeutics (ATXS)?

For Astria Therapeutics (ATXS), the 52-week high is $16.9, which is 80.36% from the current price. The 52-week low is $4.26, the current price is 119.95% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Astria Therapeutics (ATXS) a growth stock?

Astria Therapeutics (ATXS) has shown an average price growth of -6.65% over the past three years. It has received a score of 81 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Astria Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Astria Therapeutics (ATXS) stock price performance year to date (YTD)?

As of the latest data, Astria Therapeutics (ATXS) has a year-to-date price change of 20.28%. Over the past month, the stock has experienced a price change of -18.94%. Over the last three months, the change has been -16.19%. Over the past six months, the figure is -0.64%.
help

Is Astria Therapeutics (ATXS) a profitable company?

Astria Therapeutics (ATXS) has a net income of -$72.89M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$83.03M. Furthermore, the EBITDA is $0.
help

What is the market capitalization of Astria Therapeutics (ATXS)?

Astria Therapeutics (ATXS) has a market capitalization of $528.7M. The average daily trading volume is 9.43, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level